Takeda’s Rhonda Pacheco proposes $307K share sale

The notice says the securities were acquired through vested restricted stock unit awards on July 1, 2026.

Accepted by SEC EDGAR 07/13/2026 - 06:22 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Takeda Pharmaceutical Company Limited (TAK) is the issuer in a Form 144 notice listing a proposed sale for Rhonda Pacheco, identified as President, US Business Unit and US Country Head. The notice lists 18,316 American Depositary Shares (ADSs) for sale, with an approximate sale date of July 13, 2026, and an aggregate market value of $306,789.1. Interactive Brokers LLC is named as the broker. The notice lists 143,310,556 ADSs outstanding and states that Pacheco acquired 50,582 ADSs through vested restricted stock unit awards on July 1, 2026.

Key Figures

ADSs proposed for sale: 18,316 ADSs Aggregate market value: $306,789.1 ADSs outstanding: 143,310,556 ADSs +2 more

5 metrics

ADSs proposed for sale 18,316 ADSs Approximate sale date July 13, 2026

Aggregate market value $306,789.1 Proposed sale

ADSs outstanding 143,310,556 ADSs Listed in the notice

ADSs acquired through vested restricted stock unit awards 50,582 ADSs Acquired July 1, 2026

Approximate sale date July 13, 2026 Proposed ADS sale

Key Terms

American Depositary Shares (ADSs), Aggregate Market Value, Restricted Stock Unit Awards - Vested

3 terms

American Depositary Shares (ADSs) financial

"Title of the Class of Securities To Be Sold"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Restricted Stock Unit Awards - Vested financial

"Restricted Stock Unit Awards - Vested"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TAK ADSs is Rhonda Pacheco proposing to sell?

Rhonda Pacheco's notice lists a proposed sale of 18,316 ADSs, with an approximate sale date of July 13, 2026.

What is the aggregate market value of Rhonda Pacheco's proposed TAK sale?

The aggregate market value listed for the proposed sale is $306,789.1.

How did Rhonda Pacheco acquire the TAK ADSs?

The notice lists 50,582 ADSs acquired through vested restricted stock unit awards on July 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002111489
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome, Chuo-ku Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Rhonda Pacheco
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	President, US Business Unit and US Country Head

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich CT 06830	18316	306789.1	143310556	07/13/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/01/2026	Restricted Stock Unit Awards - Vested.	Takeda Pharmaceutical Company Limited			50582	07/01/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	07/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kate Huleatt, by power of attorney, for Rhonda Pacheco
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)